Please note that all agenda timings are Eastern Time. For PDT time and full session descriptions download the full program details here

8:00 am Conference Registration & Networking

Deep Dive on Basic ILD Science: What You Need to Know to Maximize the Efficacy of Your Therapeutic

8:25 am Chair’s Opening Remarks

8:30 am eep Diving in to the Progressive Phenotype of Fibrosing Interstitial Lung Disease

  • Craig Conoscenti Medical Expert ILD Respiratory Clinical Development & Medical Affairs, Boehringer Ingelheim


  •  Delving into what constitutes fibrosing interstitial lung disease
  • Analyzing the lumping versus splitting debate
  •  Understanding what defines the phenotype of progressive fibrotic disease?

9:00 am Reviewing Recent Research on Diagnostic Accuracy, Disease Behaviour, & Response Measures

  • Kevin Brown Professor &Chair, Department of Medicine, National Jewish Health


  • Exploring the limits of diagnostic accuracy
  • Predicting longitudinal disease behavior
  • Measuring response to intervention

9:30 am Exploring the Role of TGFbeta in Pulmonary Fibrosis to Evaluate Whether itsIt’s Impact is Healing or Devastating Across Various ILD Phenotypes


  • Explaining how TGFbeta affects lung homeostatis
  • Exploring the mechanisms of TGFb dysregulation in the lung
  • Discussing potential strategies and pitfalls related to TGFbeta activation in the lung

10:00 am Integrin-Mediated TGF-β Activation: A Crucial Role in Fibrosis

  • Greg Cosgrove Vice President Clinical Development , Pliant Therapeutics


• Selective integrin inhibition leads to localized TGF-β inhibition.
• The role of v6 and v1 in ILDs
• Target engagement in ILD drug development.

10:30 am Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the ILD field and establish meaningful business relationships to pursue for the rest of the conference, all from the comfort of your own home or office.

11:00 am Morning Break & Networking

11:15 am Role of monocytes in Pathogenesis of IPF

  • Ling-Pei Ho Associate Professor Respiratory Immunology, University of Oxford

11:30 am CXCR4/CXCL12: A Common Molecular Axis in Multiple Cell Types with Relevance in ILD

  • Mick Foley La Trobe University & Chief Scientific Officer , AdAlta


  • Understanding lower expression of CXCR4 is low in non-diseased lung but upregulation in IPF and other ILDs
  • Analyzing CXCR4 expression in a range of cell-types that are known to contribute to IPF/ILD
  • Sharing a novel i-body targeting CXCR4 and discussing anti-fibrotic efficacy and safety data from preclinical and first in-human trial

12:00 pm Evaluating Importance of Serotonin System in Relation to Systemic Sclerosis, Fibrosis & ILDs


  • Discussing the role and proposed mode of action of 5-HT and 5-HT2B receptors in fibrosis
  • Reviewing anti-fibrotic activities of 5-HT2B receptor antagonists in disease models of systemic sclerosis
  • Understanding how progressive fibrosing ILD’s may share common pathogenetic pathways and the potential role of 5-HT and 5-HT2B receptors

12:30 pm Lunch & Networking

Understanding Common Challenges in ILD Clinical Trials & Learning How to Overcome Them

1:30 pm Analyzing Lessons Learned from IPF Clinical Trials to Streamline the Design & Execution of Efficient Clinical Trials for Novel ILD Medicines

  • Toby Maher Director, Interstitial Lung Disease Program, USC


  • Understanding how to utilize data from IPF clinical trials to inform trials looking at wider progressive fibrotic ILD phenotypes
  • Investigating common challenges of ILD and IPF clinical trials, and learning how to overcome them
  • Discussing common mistakes made during IPF clinical trials so you know how to overcome them when designing and executing ILD clinical trials

2:00 pm Exploring Scleroderma Through the Lens of ILD Clinical Trials: Reviewing Success’, Challenges & Lessons Learned


  • Revealing lessons learned from recent scleroderma ILD clinical trials
  • Discussing trial design in at-risk population for ILD versus those with clinical or established ILDs
  • Understanding what factors you must consider optimizing the success of your therapeutic during clinical trials 

2:30 pm Audience Discussion: Comparing & Contrasting Lumping vs Splitting: Which Approach Should You Choose to Maximize Trial Efficiency Based on the ILD Phenotype in Question


As the INBUILD study adds fuel to the lumping versus splitting debate and meaningful antifibrotic effect is demonstrated across Interstitial Lung Disease irrespective of underlying diagnosis, it can be difficult to determine where your stance on the matter lies. Join this interactive audience discussion to debate with your peers, the alternative perspectives on this polarizing issue. This is your opportunity to learn about how the rest of the ILD community determines whether they choose lumping or splitting when designing clinical trials and to form an informed view important to maximizing the efficiency of your future R&D.

3:00 pm Afternoon Break & Networking

Reviewing the Latest Research on ILD Treatment Strategies: What Steps Must You Take to Optimize Your Treatment Plan?

3:30 pm Reviewing Combination Regimes for ILD Treatment: Past, Present, Futur


  • Revealing the full spectrum of combination trials from triple therapy to 2 anti-fibrotic combination therapy
  • Investigating antifibrotics and sildenafil
  • Discussing new trials assessing novel therapies on top of standard care

4:00 pm Audience Discussion: Exploring Pre-Symptomatic Treatment Strategies and Discovering How to Determine the Stage of Disease Progression at Which Therapeutic Intervention is Most Powerful For Specific ILDs


Kick off the last audience discussion of the day with a deep dive into the potential to treat ILD pre-symptomatically. Determining which stage of progression is best for you to initiate ILD treatment is a challenging decision, often influenced by a plethora of external factors which can be difficult to navigate. Tap into the wealth of knowledge your fellow attendees have on this subject and share your own thoughts on how to decide when to intervene in our final, thought-provoking session of the day.

4:30 pm Targeting Collagen I mRNA Translation in a Tissue Selective Manner With Small Molecules


• Discovery of Lung selective COL1A1 mRNA translation modulators
• Novel target space of Collagen I mRNA processing
• Collagen I mRNA translation is differently regulated across tissues thereby
offering novel therapeutic intervention points in many lung diseases

5:00 pm End of Day One